Clinical Trial Update: Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating bevacizumab added to carboplatin and paclitaxel with pembrolizumab for advanced or recurrent endometrial cancer; currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• Carboplatin (Paraplatin) (carboplatin)
• Paclitaxel (Taxol) (paclitaxel)
• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma | Phase 3 | Status: RECRUITING